| SC 13G/A | 2024-02-14 | ARCH Venture Fund IX, L.P. | Beam Therapeutics Inc. | 5,443,039 | 6.7% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Beam Therapeutics Inc. | 7,164,843 | 8.8% | EDGAR |
| SC 13G/A | 2024-02-12 | Farallon Capital Partners, L.P. | Beam Therapeutics Inc. | 542,347 | 0.7% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Beam Therapeutics Inc. | 8,953,800 | 11.0% | EDGAR |
| SC 13G/A | 2024-02-06 | Temasek Holdings (Private) Ltd | Beam Therapeutics Inc. | 3,076,117 | 3.8% | EDGAR |
| SC 13G/A | 2024-01-29 | ARK Investment Management LLC | Beam Therapeutics Inc. | 9,393,889 | 11.5% | EDGAR |
| SC 13G/A | 2024-01-25 | BlackRock Inc. | Beam Therapeutics Inc. | 6,662,043 | 8.2% | EDGAR |
| SC 13G | 2024-01-24 | STATE STREET CORP | Beam Therapeutics Inc. | - | 5.7% | EDGAR |
| SC 13G | 2023-09-22 | Farallon Capital Partners, L.P. | Beam Therapeutics Inc. | 306,547 | 0.4% | EDGAR |
| SC 13G | 2023-03-17 | Temasek Holdings (Private) Ltd | Beam Therapeutics Inc. | 3,644,573 | 5.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Farallon Capital Partners, L.P. | Beam Therapeutics Inc. | 436,862 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-10 | ARK Investment Management LLC | Beam Therapeutics Inc. | 8,213,131 | 11.6% | EDGAR |
| SC 13G/A | 2023-02-10 | Temasek Holdings (Private) Ltd | Beam Therapeutics Inc. | 2,878,297 | 4.1% | EDGAR |
| SC 13G/A | 2023-02-09 | FMR LLC | Beam Therapeutics Inc. | 7,769,016 | 11.0% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Beam Therapeutics Inc. | 6,273,630 | 8.9% | EDGAR |
| SC 13G/A | 2023-02-02 | BlackRock Inc. | Beam Therapeutics Inc. | 5,238,280 | 7.4% | EDGAR |
| SC 13G | 2022-07-14 | Farallon Capital Partners, L.P. | Beam Therapeutics Inc. | 276,948 | 0.4% | EDGAR |
| SC 13G/A | 2022-02-14 | HHLR ADVISORS, LTD. | Beam Therapeutics Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2022-02-14 | ARCH Venture Fund IX, L.P. | Beam Therapeutics Inc. | 5,843,039 | 8.6% | EDGAR |
| SC 13G/A | 2022-02-14 | Redmile Group, LLC | Beam Therapeutics Inc. | 1,885,850 | 2.8% | EDGAR |